The Price (or Lack) of Global Health

Posted by Ed Schoonveld on Fri, Dec 20, 2019

Governments, private health insurers and employers worldwide are deeply concerned about the increasing cost of healthcare. U.S. healthcare cost as a share of GDP has nearly tripled from 1970 to 2017, resulting in a growing societal burden.


>
Read More

The 2019 STAT Summit: ‘You Don’t Burn the House Down to Get Rid of Rats’

Posted by Ed Schoonveld on Tue, Nov 26, 2019

Many senior leaders in the healthcare and pharmaceutical space gathered at the inaugural STAT Summit on Nov. 21st at the MIT campus in Cambridge, Mass. The invitation-only summit featured an interesting mix of exciting medical scientific advances, including bionic limbs, artificial intelligence, the impact of real-world evidence on drug development, and patient testimonials regarding some great medical and pharmaceutical innovations.


>
Read More

Obamacare’s Repeal: What to Expect

Posted by Ed Schoonveld on Mon, Jan 16, 2017

 
It has been difficult to predict what repealing and replacing the Affordable Care Act (ACA), the signature legislation from President Barack Obama, will mean for the public and for the insurance and pharmaceutical industries. The lack of Republican consensus behind a single alternative plan and the uncertainty of President-elect Donald Trump’s actions have turned any projection into mere speculation. However, recent Republican steps and political reality are now starting to help clarify what the likely outcome of “repeal and replace” may be.


>
Read More